Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2021-11-29 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团2021年第三次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2021 Third Extraordinary General Meeting (EGM) Meeting Materials" of KPC Pharmaceuticals, Inc. It contains detailed agenda, meeting rules, voting procedures, and proposed resolutions for the shareholders' meeting. The content includes explanations of amendments to the company's board and supervisory meeting rules, election of directors and supervisors, and other governance matters. The document is comprehensive and clearly intended as materials for a shareholders' meeting rather than a simple announcement or voting results. It is not a full annual or interim financial report, nor an earnings release or audit report. It is not a proxy solicitation or voting results declaration, but the actual meeting materials. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or Extraordinary General Meeting. The document length (15,000 characters) and detailed content support this classification with high confidence.
2021-11-29 Chinese
昆药集团关于使用部分闲置募集资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of using temporarily idle raised funds to purchase financial products. It details the amounts, types, and terms of entrusted financial products, the approval process by the board and shareholders, risk control measures, and the impact on the company. The document does not contain comprehensive financial statements or detailed financial performance data but focuses on the update about the company's capital management activities related to fundraising proceeds. It is not an annual or interim report, earnings release, or audit report. It is a specific update on financing activities, particularly the use of idle raised funds for financial products, which fits the category of Capital/Financing Update (CAP). The document length is about 5948 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the correct classification is CAP with high confidence.
2021-11-24 Chinese
昆药集团关于董事会、监事会换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election and nomination of the company's board of directors and supervisory board members. It details the candidates for the new board and supervisory board, their qualifications, and the process for the upcoming shareholder meeting to approve these nominations. There is no financial data, no discussion of financial results, no audit information, no legal proceedings, no merger or acquisition activity, and no mention of report publication or dividend. The content is focused on management and board changes. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 4194 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2021-11-22 Chinese
昆药集团独立董事提名人声明（辛金国）
Regulatory Filings
2021-11-22 Chinese
昆药集团独立董事候选人声明（刘珂）
Board/Management Information Classification · 95% confidence The document is a declaration statement by an independent director candidate, Liu Ke, confirming qualifications, independence, and compliance with relevant laws and regulations for serving as an independent director at Kunming Pharmaceutical Corporation. It contains no financial data, no report or meeting results, no voting outcomes, no financial performance or management discussion. It is a formal declaration related to board membership qualifications and independence, which fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report but a standalone declaration. Therefore, the classification is MANG with high confidence.
2021-11-22 Chinese
昆药集团股份有限公司股东大会议事规则
Governance Information Classification · 95% confidence The document is titled as the "Rules of Procedure for the Shareholders' General Meeting" of Kunming Pharmaceutical Group Co., Ltd., revised in November 2021. It details the procedures, rights, and regulations governing the conduct of shareholders' meetings, including notice requirements, proposal submissions, voting procedures, meeting records, and disclosure obligations. It does not contain financial statements, audit opinions, or management discussions of financial results. Instead, it is a governance document outlining internal rules and processes related to shareholder meetings. Therefore, it fits best under Governance Information (CGR). The document length (7068 characters) and content confirm it is a full procedural document, not a brief announcement or a report publication notice.
2021-11-22 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.